📰 Eceptor News
Page 89 - Eceptor News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Eceptor. Real-time updates on events, politics, business and more.
October 5, 2022
Researchers engineered biparatopic nanobodies against SARS-CoV-2.
October 5, 2022
Researchers at VCU Massey Cancer Center discovered a cellular partnership that drives the growth of deadly brain tumors and could potentially serve as a novel target for disease treatment.
October 4, 2022
In a recent study posted to the bioRxiv* preprint server, researchers explored the cross-reactivity, avidity, and kinetics of memory B-cells and serum antibodies in vaccinated and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected individuals.
October 4, 2022
A new study reviewed the challenges of coronavirus disease 2019 (COVID-19) vaccination and herd immunity.
October 4, 2022
A new review in the Biology of Reproduction journal analyzed the relationship between the immune system and the female reproductive system while focusing on the effects of COVID-19-associated immune responses on the reproductive system. The study searched PubMed to identify peer-reviewed literature in English up to May 2022 and finally included 83 studies.
October 4, 2022
A new study discusses how immune escape mutations allow a recent SARS-CoV-2 variant to evade neutralizing antibodies and cause breakthrough infections.
October 4, 2022
In new research, researchers identified genetic associations of stroke pathogenesis.
October 4, 2022
A new study explores the functional relevance of some Omicron mutations in terms of their ability to escape neutralizing antibody responses.
October 3, 2022
Researchers perform antibody profiling against SARS-CoV-2, several endemic pathogens, as well as vaccine antigens among rheumatic disease patients.
October 3, 2022
A recent Nature Reviews Immunology study has summarized the efficacy of neutralizing antibodies that target four main regions of the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), namely, the receptor-binding domain (RBD) in the S1 subunit, the fusion peptide region in the S2 subunit, the stem helix region, and the N-terminal domain.